Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD)

Jul 19, 2024 03:40

The supplemental new drug application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) has been accepted and file… [+22552 chars]

Ads Links by Easy Branches
Play online games for free at games.easybranches.com
Guest Post Services www.easybranches.com/contribute

Herbal Horoscope: Your Wellness Forecasts Based on Your Sign

Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis

Our ⚡AMP sites

Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD)

Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD)

Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD)

Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD)

Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD)

Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination With Sertraline for the Treatment of Adults With Post-Traumatic Stress Disorder (PTSD)